← Leaderboards
Adam J Adler
University Of Connecticut Sch Of Med/Dnt
$6,337,232
Attributed
$8,608,358
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $847.6K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,608,358 · 9
By mechanism
R01$6,381,644 · 3
R21$1,508,662 · 3
R56$382,500 · 1
T32$169,552 · 1
R03$166,000 · 1
Top collaborators
- Anthony T. Vella16 shared
- Annabelle Rodriguez2 shared
Most similar at University Of Connecticut Sch Of Med/Dnt
Same institution · by research overlap
- Anthony T. Vella$15,822,694
- Marc F Hansen$4,114,656
- Bruce J Mayer$7,825,034
- Anna Konstorum$115,732
- Cheryl Oncken$14,595,853
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCd4 Positive T LymphocytesAntigensTumor ImmunityMediatingInterleukin-2TumorResponseCytokineCellsBasePathway InteractionsMalignant NeoplasmsEpitopesAutoimmunityProgramsAutoantigensTumor AntigensCd8b1 GeneTissuesTumor GrowthT Cell ResponsePrincipal InvestigatorGrowth
Grant awards (32)
Understanding how the interaction between Lag3 deficiency and hypercholesterolemia impact anti-tumor immunity and cardiovascular disease in a melanoma model$147,783
R21 · FY2024 · CA
Generating a novel conditional knockout mouse for a super-enhancer that controls cytokine responsiveness$83,000
R03 · FY2024 · AI
Understanding how the interaction between Lag3 deficiency and hypercholesterolemia impact anti-tumor immunity and cardiovascular disease in a melanoma model$271,004
R21 · FY2023 · CA
Generating a novel conditional knockout mouse for a super-enhancer that controls cytokine responsiveness$83,000
R03 · FY2023 · AI
Test if antitumor T cells use a putative super-enhancer in the Il1rl2-Il1rl1 intergenic region to form "innate-like" responses to cytokines$239,250
R21 · FY2019 · AI · contact PI
Test if antitumor T cells use a putative super-enhancer in the Il1rl2-Il1rl1 intergenic region to form "innate-like" responses to cytokines$199,375
R21 · FY2018 · AI · contact PI
Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells$379,088
R01 · FY2016 · AI · contact PI
Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells$379,260
R01 · FY2015 · AI · contact PI
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced Costimulation$223,722
R01 · FY2015 · CA · contact PI
Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells$379,427
R01 · FY2014 · AI · contact PI
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced Costimulation$289,346
R01 · FY2014 · CA · contact PI
Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells$356,815
R01 · FY2013 · AI · contact PI
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced Costimulation$280,397
R01 · FY2013 · CA · contact PI
Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells$379,747
R01 · FY2012 · AI · contact PI
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced Costimulation$298,295
R01 · FY2012 · CA · contact PI
Basic Immunology and Immunologic Cell Injury$169,552
T32 · FY2012 · AI · contact PI
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced Costimulation$76,871
R01 · FY2011 · CA · contact PI
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced Costimulation$306,320
R01 · FY2010 · CA · contact PI
Mechanisms of Effector CD4 Cell Tolerization$382,500
R56 · FY2009 · AI · contact PI
Mechanisms of Effector CD4 Cell Tolerization$303,467
R01 · FY2008 · AI · contact PI
A Transgenic Model for Prostate Tumor Immunity$281,848
R01 · FY2008 · CA · contact PI
Mechanisms of Effector CD4 Cell Tolerization$309,344
R01 · FY2007 · AI · contact PI
A Transgenic Model for Prostate Tumor Immunity$281,848
R01 · FY2007 · CA · contact PI
Mechanisms of Effector CD4 Cell Tolerization$318,584
R01 · FY2006 · AI · contact PI
A Transgenic Model for Prostate Tumor Immunity$290,265
R01 · FY2006 · CA · contact PI
Mechanisms of Effector CD4 Cell Tolerization$326,250
R01 · FY2005 · AI
A Transgenic Model for Prostate Tumor Immunity$297,250
R01 · FY2005 · CA
Mechanisms of Effector CD4 Cell Tolerization$326,250
R01 · FY2004 · AI
A Transgenic Model for Prostate Tumor Immunity$297,250
R01 · FY2004 · CA
Comparing Toleragenic Versus Immunogenic APC Function$217,500
R21 · FY2003 · AI
Comparing Toleragenic Versus Immunogenic APC Function$217,500
R21 · FY2002 · AI
Comparing Toleragenic Versus Immunogenic APC Function$216,250
R21 · FY2001 · AI